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Complementary and Alternative Medicine: Review
Herbal Medicinal Product Use During
Pregnancy and the Postnatal Period
A Systematic Review
Yolanda Muñoz Balbontín, MD, MSc, Derek Stewart, PhD, Ashalatha Shetty, CCST,
Catherine A. Fitton, MSc, and James S. McLay, FBIHS
OBJECTIVE: To report the incidence and nature of herbal
medicinal products’ adverse events and herb–drug inter-
actions used by some pregnant and postnatal women.
DATA SOURCES: The Allied and Complementary Med-
icine Database, the Cumulative Index to Nursing and
Allied Health Literature, EMBASE, the Cochrane Library,
MEDLINE, Scopus, Web of Science, and ClinicalTrials.gov
were searched from inception until August 2018.
METHODS OF STUDY SELECTION: Any studies report-
ing adverse events, herb–drug interactions or absence
thereof associated with herbal medicinal products used
during pregnancy or the postnatal period were included.
Conference abstracts, pilot studies, and nonhuman stud-
ies were excluded. All included studies were critically
appraised by two independent reviewers.
TABULATION, INTEGRATION AND RESULTS: Database
searches retrieved 3,487 citations. After duplicate
removal and review of titles, abstracts, and full-text,
115 articles were critically appraised. After excluding
irrelevant and low-quality articles, 74 articles were
included for data extraction and synthesis. Adverse drug
reactions, congenital malformations, fetal growth retar-
dation or herb–drug interactions were the primary study
objective reported by 19 of the 74 included studies, 16
cohort studies, one cross-sectional survey, and two ran-
domized controlled trials. A total of 47 herbal medicinal
products and 1,067,071 women were included in this
review. Use of almond oil was associated with preterm
birth (odds ratio 2.09, 95% CI 1.07–4.08), oral raspberry
leaf was associated with cesarean delivery (adjusted odds
ratio [AOR] 3.47, 95% CI 1.45–8.28); heavy licorice use
was associated with early preterm birth by 3.07-fold
(95% CI 1.17–8.05). African herbal medicine mwanaphe-
po was associated with maternal morbidity (AOR 1.28;
95% CI 1.09–1.50), and neonatal death or morbidity.
Fourteen studies reported absence of adverse events.
Four studies reported herb–drug interactions, but none
studied adverse events arising from them.
CONCLUSION: The use of herbal medicinal products
during pregnancy and the postnatal period should be
discouraged until robust evidence of safety is available.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO,
CRD42017081058.
(Obstet Gynecol 2019;00:1–13)
DOI: 10.1097/AOG.0000000000003217
Herbal medicinal products are any plant-derivedproduct (ie, leaves, roots, flowers), in any form,
taken as a preventive or curative treatment.1 Although
herbal medicinal products have been used for centu-
ries in Asia, Africa, and Latin America, it is only over
the past decades that use has attracted attention in the
Western world.2 Despite the lack of robust efficacy
and safety data, the use of herbal medicinal products
is widespread and increasing throughout North Amer-
ica and Europe.3–7
Women have been identified as the major users of
herbal medicinal products, both for maintenance of
From the Institute of Applied Health Sciences, Aberdeen University, Aberdeen,
Scotland, United Kingdom; School of Pharmacy and Life Sciences, Robert
Gordon University, Aberdeen, Scotland, UK, and College of Pharmacy, Qatar
University, Doha, Qatar; and NHS Grampian, Foresterhill Health Campus,
Aberdeen, Scotland, United Kingdom.
Each author has confirmed compliance with the journal’s requirements for
authorship.
Corresponding author: James McLay, FBIHS, Royal Aberdeen Children’s Hos-
pital, Aberdeen, Scotland, United Kingdom; email: j.mclay@abdn.ac.uk.
Financial Disclosure
Consejo Nacional de Ciencia y Tecnología (CONACyT, Mexico) sponsored Dr.
Muñoz Balbontín’s doctoral studies. The other authors did not report any poten-
tial conflicts of interest.
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an
open-access article distributed under the terms of the Creative Commons
Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND),
where it is permissible to download and share the work provided it is properly
cited. The work cannot be changed in any way or used commercially without
permission from the journal.
ISSN: 0029-7844/19
VOL. 00, NO. 00, MONTH 2019 OBSTETRICS & GYNECOLOGY 1
health and treatment of disease.8–12 This widespread
use extends into pregnancy, where reportedly
between 10 and 74% of pregnant women in Africa,
Australia, Europe, the United Kingdom, and the
United States use herbal medicinal products.13–23 In
the United Kingdom, approximately 40% of pregnant
women use herbal medicinal products to treat preg-
nancy related problems or as nutritional supplements
to better pregnancy outcomes.16,17 This use of herbal
medicinal products appears to extend into the post-
natal period with 31% of breastfeeding women report-
ing the use of complementary and alternative
medicines, including herbal medicinal products, to
treat a variety of ailments24 or to improve milk flow.25
A further potential issue is that of herb–drug inter-
actions. Data from Australia, Europe and North and
South America suggest that 12–81% of pregnant women
use prescription medicines.26–30 It is estimated that
between 2.5% and 20.3% of these pregnant women also
use herbal medicinal products.31–34 This concurrent use
of herbal medicinal products and prescribed medicines
gives rise to the possibility of herb–drug interactions
with the potential to harm the mother-fetus dyad.35,36
Owing to a variety of reasons, including a lack of
appropriately designed and powered studies, low
reporting rates to inadequate regulatory supervision,
and the widely held belief that herbal medicinal
products are natural and hence safe, the prevalence
of adverse events and herb–drug interactions associ-
ated with herbal medicinal product use is unclear.
Because there are reports of severe adverse events
such as perinatal stroke,37 severe hyponatremia,38
and lead poisoning,39–41 it is important to explore
the prevalence of these and other adverse outcomes.
Previous published systematic reviews on the safety
of herbal medicinal products have focused on random-
ized controlled trials, and excluded cohort studies or
case reports.42–49 Furthermore, these systematic reviews
have been assessed as being of low quality.50,51 Cur-
rently there are no published systematic reviews on
adverse events and herb–drug interactions associated
with herbal medicinal product use during pregnancy
and the postnatal period. The aim of this systematic
review was to retrieve primary literature reporting the
incidence and nature of adverse events and herb–drug
interactions, to determine whether herbal medicinal
product use during pregnancy and the postnatal period
is associated with adverse maternal or child outcomes.
SOURCES
The Allied and Complementary Medicine Database, the
Cumulative Index to Nursing and Allied Health Liter-
ature, EMBASE, the Cochrane Library, MEDLINE,
Scopus, Web of Science, and ClinicalTrials.gov were
searched from inception until August 2018. Only pub-
lications in English were included.
A three-step search strategy was applied. An
initial limited search of MEDLINE was done, fol-
lowed by analysis of the text words contained in the
title and abstract, and of the index terms used to
describe the article. A second search using all identi-
fied keywords and index terms was done across all
included databases. Thirdly, the reference list of all
identified articles and reports was searched for addi-
tional studies. The following search string was used:
(antenatal* OR prenatal* OR pregnan* OR postnatal* OR
“postpartum*” OR “puerperium*” OR “breastfeeding*” OR
“breast feeding*” OR lactati* OR maternal) AND (“herbal
medicine*” OR “medicinal herb*” OR “herbal therap*” OR
phytotherap* OR “traditional medicine*” OR “herb*”
OR “galactagogue herb*” OR “herb* galactagogue*” OR
“medicinal plant*” OR “botanical*” OR food supplement*
OR liquorice* OR licorice* OR stevia OR senna) AND
(“safe*” OR “adverse effect*” OR “adverse event*” OR
“adverse reaction*” OR “side effect*” OR “adverse drug*
reaction*” OR “drug* interaction*” OR “herb drug interac-
tion*” OR “herb-drug interaction*” OR “drug herb interac-
tion*” OR “drug-herb interaction*” OR “drug*
hypersensitivity*” OR hypersensitivity* OR “unwanted
effect*” OR “undesired effect*” OR “unwanted reaction*”
OR “undesired reaction*”) NOT (vitamin* OR animal prod-
uct* OR rat* OR mouse OR rabbit* OR mice OR sheep OR
chick* OR pig* OR dog* OR sow* OR cow* OR monkey*
OR agricultural* OR “veterinary*” OR “animal* model*”
OR “in vitro” OR “cell model*”).
STUDY SELECTION
We included human studies that focused on pregnant
or postnatal women. Randomized controlled trials,
nonrandomized comparative studies, meta-analysis,
observational studies, mixed-methodology studies,
case reports and case series were considered for
inclusion. Only studies that reported adverse events
(including side effects, adverse drug reactions, mal-
formations, or adverse birth outcomes), or absence
thereof, or herb–drug interactions were included.
We excluded the following types of articles:
conference or symposium abstracts; preliminary re-
ports; pilot studies; correspondence articles; studies
focusing on homeopathic treatments; or other alter-
native treatments (eg, aromatherapy, acupuncture,
relaxation therapy); and low-quality case reports (see
Article Quality Assessment [Appendix 1, available
online at http://links.lww.com/AOG/B334]). The
shape, active components, and molecular mechanisms
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of the herbal medicinal products were not a review
objective and will not be discussed in this article.
Only studies reporting any safety issue arising
from herbal medicinal products used during preg-
nancy or the postnatal period in any country, adverse
events or herb–drug interactions were assessed. Stud-
ies comparing herbal medicines with a placebo, posi-
tive controls, or no comparator were also included.
Quality assessments were conducted by two inde-
pendent reviewers (Y.M.B. and D.S.) using modified
versions of the Critical Appraisal Skills Programme
quality assessment tool for randomized controlled trials52
and cohort studies53 and the Joanna Briggs Institute
Checklist for case reports.54 High quality was stated as
at least 14 out of 17 points for interventional studies, at
least 11 out of 14 points for observational studies, and at
least 7 out of 8 points for case reports. These cut-points
were established by the review team considering the most
relevant items of the checklists. All interventional and
observational studies were included irrespective of quality
score. Only high-quality case reports were included.
A tailored spreadsheet was prepared for data extrac-
tion and data synthesis. All studies identified during the
database search were assessed for relevance to the review
protocol and quality assessed based on information from
the title, abstract and full text review by two independent
reviewers (Y.M.B and D.S.). A third reviewer was
consulted if consensus could not be reached (J.S.M.).
Where information was missing from the studies, contact
with authors was attempted, where practical, via email;
however, no responses were received.
The following key data were extracted from
selected literature: details of the authors; country of
publication; year of publication; herbal medicinal prod-
uct; study population; setting; recruitment; incidence;
nature of adverse events; and herb–drug interactions
(classification, severity, patient outcomes). Data ex-
tracted for trials were the generation of allocation
sequence, concealment of allocation, outcome measures,
and other risks of bias. For cohort studies, the data ex-
tracted were appropriateness of exposed and control
recruitment, inclusion and exclusion criteria clearly
stated, appropriate validation of exposure, appropriate
analyses, and enough follow-up information.
Owing to lack of study homogeneity, a meta-
analysis was not appropriate; therefore, a narrative
synthesis of the results was conducted. Where avail-
able, odds ratios (ORs) were reported and presented
in a forest plot for descriptive purposes only, no meta-
analysis was conducted.
A systematic review protocol was registered by
PROSPERO.55 The PRISMA checklist was used to
guide the reporting of the systematic review.
RESULTS
Database searches retrieved a total of 3,487 citations.
After removal of duplicates, title and abstract screen-
ing, and full-text screening, 115 articles were criti-
cally appraised. Only 74 articles were included for
data extraction, synthesis and narrative analysis (Fig.
1). Included studies were performed in 24 different
countries. Twenty-nine interventional studies, 26
observational studies, and 19 case reports were
reviewed.
Fourteen interventional56–69 and 11 observational
studies34,70–79 were graded as high quality; 10 inter-
ventional80–89 and 13 observational studies14,31,90–100
were graded average quality, and five intervention-
al101–105 and two observational studies24,106 were
graded poor quality. These poor-quality studies were
still included in the review, only low-quality case re-
ports were excluded (Fig. 2).
Excluding case reports, specific safety concerns, such
as adverse drug reactions, congenital malformations, fetal
growth restriction and herb–drug interactions, were the
primary study objective reported by 19 studies, 16 cohort
studies,31,34,70–75,77–79,92,95,96,98,100 one cross-sectional sur-
vey,76 and two randomized controlled trials.64,68
A total of 47 herbal medicinal products and
1,067,071 women were included in this review. Sample
size ranged from 27 to 500 women in interventional
studies, 187 to 860,215 women in observational
studies, and one to five women in case reports. Seven
studies collected data during the first trimester of
pregnancy;71,82,85,88,96,105,107 10 during the second tri-
mester;41,58,67,81,83,84,87,89,101,108 12 during the third tri-
mester;38,62,64,80,91,92,100,102,103,106,109,110 five
throughout pregnancy;69,70,75,90,95 five around the time
of labor (a few hours before or after delivery);37,59–61,77
nine throughout pregnancy and the postnatal
period;14,31,39,72–74,78,79,111 three during the third tri-
mester and the postnatal period;40,112,113 20 during
the postnatal period only;24,34,56,63,65,66,68,76,86,94,97–
99,104,114–119 and two did not specify the precise point
during pregnancy of data collection.57,93
The methods used to identify adverse events and
herb–drug interactions were clinical examination;37–
41,56,57,59,60,63,70,81,82,105,107–112,114–119 patient inter-
views;61,65,78,86,93,100,106 patient questionnaires;24,31,34,72–
74,76,85,90,94,95,97–99 diary cards;62,66,68 laboratory or imag-
ing studies (ie, hematologic and biochemical results,
ultrasonography);71,79,102,120 and review of medical re-
cords.14,64,65,75,77,88,91,92,96,100,113 Eleven studies did not
mention how adverse events or herb–drug interactions
were identified.58,67,69,80,83,84,87,89,101,103,104
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Thirty-one studies identified and reported the
incidence of adverse events.14,24,56,61,64–70,72–75,81–84,86–
89,93–96,99,100,105,106 Fourteen studies reported that no
adverse events were observed57,58,60,62,63,68,71,80,85,101–
104,118 (see Appendixes 1–4, available online at http://
links.lww.com/AOG/B334, for details). Table 1 reports
the most commonly used herbal medicinal products and
their reported safety issues.
The most frequently reported adverse drug reac-
tion, for all assessed herbal medicinal products, was
gastrointestinal complaints. One study comparing the
use of capsaicin-containing chili to placebo for the
treatment of gestational diabetes mellitus demon-
strated a higher rate (60%) of loose stools, gastroin-
testinal irritation, and diarrhea in women using the
study drug compared with none in the placebo
group.69 Otherwise, the rates of adverse drug reac-
tions were the same in all interventional studies in
the study drug compared with comparator.
Topical use of almond oil during the third
trimester to avoid stretch marks was associated with
preterm birth (birth before week 37 of pregnancy)
(OR 2.09, 95% CI 1.07–4.08).94 When chamomile
was used as a substitute for caffeinated tea in the sec-
ond and third trimester, it was associated with fetal
ductus arteriosus constriction, determined by fetal
echocardiography in a case report,120 and breast
engorgement and a significant (50%) increase in milk
production, when used during the postnatal period in
another case report.116 Chamomile use during the
third trimester was reported in one study to be asso-
ciated with a higher incidence of preterm birth
(P,.002), shorter newborns (P,.05), and low birth
weight (P,.002)99 compared with nonusers, whereas
Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart.
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a similar study reported no significant increased odds
of low birth weight (OR 2.1; 95% CI: 0.99–4.60).94
Ginger is used to treat nausea. The most frequently
reported adverse drug reactions were esophageal
reflux,89 heartburn,61,66,67,81,83,84,87,89 abdominal dis-
comfort67,84 and increased nausea.84 Heartburn and
reflux (n54), an allergic reaction (n51), and dehydra-
tion (n51) were reported to be severe enough for study
withdrawal in one average-quality, randomized con-
trolled trial that included 48 women who were up to
20 weeks pregnant and were taking ginger.89 The use
of ginger throughout pregnancy was associated with
a nonsignificant increase in the incidence of stillbirths
(OR 7.8, 95% CI 0.9–70.3)70 and a significant decrease
in gestational age at delivery and neonatal head cir-
cumference (P,.05 and P,.002, respectively)99
Fig. 2. Quality scores. Interventional studies (n529) (A), observational studies (n526) (B), and case reports (n519) (C).
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Table 1. Reported Safety Issues of the Most Commonly Used Herbal Medicinal Products During Pregnancy
and the Postnatal Period
Herbal
Medicinal
Product (No.
of Reports) Indication Adverse Events Herb–Drug Interactions Reference(s)
Aloe (3) Skin
conditions
Itching and rash Insulin—additive hypoglycemic
effects
76,93,94
Almond oil (2) Skin
conditions
Itching and rash, preterm birth No reports 93,94
Chamomile
(5)
Various Fetal ductus arteriosus constriction,
fetal tachycardia; preterm delivery,
low birth weight, smaller
newborns; breast engorgement and
tenderness
Diazepam—additive sedative
effects; propranolol—inhibition
of CYP1A2 and CYP2D6;
diclofenac—inhibition of
CYP2C9; ondansetron—
inhibition
of CYP1A2; chlorpromazine—
inhibition of CYP2D6;
dihydrocodeine—additive
sedative effects; co-codamol—
additive
sedative effects; NSAIDs;
benzodiazepines
31,76,94,99,113,116
Cranberry (2) Urinary tract
infections
Spotting in the 2nd and 3rd trimesters Diazepam—inhibition of CYP2C9;
diclofenac—inhibition of
CYP2C9
72,76
Echinacea (2) Upper
respiratory
tract
infections
Hypospadias, cleft lip, hypoplastic left
heart syndrome, inguinal hernia,
hydronephrosis, syndactyly, duplicate
renal pelvis, laryngotracheomalacia,
trisomy 18
No reports 73,95
Evening
primrose oil
(1)
Labor
induction
No adverse events were diagnosed in
case or placebo groups
No reports 60
Fenugreek (1) Increase milk
production
Toxic epidermal necrolysis: fever,
headache, bullous exanthema, skin
erosions
No reports 114
Ginger (17) Nausea and
vomiting
Reflux, heartburn, mouth irritation,
headache, dry mouth, bloating,
sweating, body ache, loose stools,
diarrhea, drowsiness, sedation,
arrhythmia, stomach-ache,
increased nausea, allergy,
dehydration. Spotting in the 2nd
and 3rd trimesters. Ventricular
septal defect, right lung
abnormality, pelviectasis in
newborns. Shorter gestational age
and smaller head circumference of
newborns.
Metformin—additive
hypoglycemic effects, might
increase insulin levels; insulin
—additive hypoglycemic
effects; aspirin—inhibit
thromboxane synthetase and
decrease platelet aggregation,
increased odds of bleeding;
nifedipine—significantly
inhibits platelet aggregation,
synergic effects
58,61,66,67,70,74,81–
84,87–
89,96,99,101,105
Licorice (4) Not specified Increased odds of early preterm birth,
rule-breaking and aggressive
behavior, and ADHD in children
aged 8.1 y. Early puberty in girls,
ADHD problems in adolescents,
very early-onset severe preeclampsia
No reports 78,79,97,98
Raspberry leaf
(3)
Labor
induction
Hypoglycemia, higher percentage of
cesarean deliveries vs nonusers.
Diarrhea, constipation, nausea,
vomiting, headache, heartburn,
uterine tightening, dizziness, bloating
Insulin—possible additive
hypoglycemic effect (not
reported as such, not
registered
in NMCD)
34,64,110
ADHD, attention-deficit/hyperactivity disorder; NMCD, Natural Medicines Comprehensive Database.
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compared with nonusers. The use of ginger (7.8% vs
5.8% nonusers [P5.007])74 and cranberry (9.7% vs
5.8% nonusers [P,.001])72 after week 17 of pregnancy
was associated with vaginal bleeding (spotting) during
2nd and 3rd trimesters.
Licorice candy consumption in the second tri-
mester (18 weeks of gestation) was associated with
severe, very early-onset preeclampsia in a case
report.108 Heavy licorice candy consumption (greater
than 500 mg/wk) throughout pregnancy was associated
with preterm birth and early preterm birth (birth before
week 34 of pregnancy) (adjusted odds ratio [AOR] 2.5,
95% CI 1.1–5.197; AOR 3.07, 95% CI 1.17–8.05,98
respectively) compared with nonusers. Moreover,
heavy licorice candy consumption in pregnancy was
associated with a variety of psychosocial issues during
childhood78 and markers of early puberty for girls 12
years of age79 in the offspring (Fig. 3).
Mwanaphepo, an African herbal medicine used
for labor induction, was associated with maternal
morbidity (ie, emergency cesarean delivery, assisted
vaginal delivery, premature rupture of membranes,
any postnatal morbidity and any delivery problem)
(AOR 1.28; 95% CI 1.09–1.50) and neonatal death or
morbidity (ie, neonatal death, meconium-stained
liquor, low birth weight, preterm birth and any neo-
natal morbidity) (AOR 1.22; 95% CI 1.06–1.40).100
Raspberry leaf, when used to induce and shorten
labor, was associated with cesarean delivery (AOR
3.47, 95% CI 1.45–8.28).34 Maternal hypoglycemia
was reported in one case report.110 Gastrointestinal
complaints (28%), headache (1%), uterine tightening
(2%), and dizziness (1%) were reported in one random-
ized controlled trial.64 Senna use during pregnancy was
associated with polyhydramnios (OR 3.8, 95% CI 1.6–
8.9), weakly associated with influenza or common cold
(OR 1.9, 95% CI 1.5–2.4), and acute digestive maternal
diseases (OR 1.8, 95% CI 1.2–2.89).90
Hepatotoxicity was reported in six case reports
associated with: three different lead-contaminated Ayur-
vedic medications used to maintain pregnancy,39–41
a herbal tea contaminated with senecionine,119 a lead-
contaminated mountain germander infusion,115 and
a lead-contaminated fennel and cumin infusion117 each
used to increase milk production in the postnatal period.
No significant difference in the incidence of
congenital malformations between case and compar-
ator groups has been reported for ginger,70,74,96
Fig. 3. Forest plot for adverse events of herbal medicinal products. *Maternal morbidity includes cesarean delivery, assisted
vaginal delivery, premature rupture of membranes, any postnatal morbidity, and any delivery problem. †Neonatal death or
morbidity includes neonatal death, meconium-stained liquor, low birth weight, preterm birth, and any neonatal morbidity.
OR, odds ratio; ADHD, attention deficit hyperactivity disorder.
Mun˜oz Balbontı´n. Safety of Herbal Medicines During and After Pregnancy. Obstet Gynecol 2019.
VOL. 00, NO. 00, MONTH 2019 Mun˜oz Balbontı´n et al Safety of Herbal Medicines During and After Pregnancy 7
echinacea,73,95 cranberry,72 senna,90 and St. John’s
wort.75 However, Chuang and colleagues reported
an association between Huang Lian (Rhizoma coptidis
for skin conditions) use during the first trimester and
nervous system congenital malformations AOR 8.62,
95% CI 2.54–29.24) and external genital organ con-
genital malformations (AOR 3.82, 95% CI 1.18–
12.40) in the offspring.91 Moreover, use of An-Tai-
Yin (Angelica sinensis) and parsley (for prevention of
miscarriages) during the first trimester was associated
with musculoskeletal and connective tissue congenital
malformations (AOR 1.61, 95% CI 1.10–2.36), and
eye congenital malformations (AOR 7.30, 95% CI
1.47–36.18) in the offspring.91 Considering the wide
CIs reported in these studies, these effect sizes should
be considered weak.
Four studies reported herb–drug interactions,
but none studied adverse events arising from them.
Herb–drug interactions were reported in two cross-
sectional surveys34,76 and two prospective cohort
studies.14,31 Of these, only three reported their inci-
dence,31,34,76 two reported how they were as-
sessed,31,76 and none reported the incidence of
adverse events arising from the identified herb–drug
interactions.
Reported herb–drug interactions involved aloe,
chamomile, cranberry, ginger, ginseng, common sage,
iron-rich herbs and dandelion (see Appendixes 1–4,
http://links.lww.com/AOG/B334, for details). Cham-
omile used alongside prescribed medicines such as
diazepam, propranolol, diclofenac, ondansetron,
chlorpromazine, dihydrocodeine, and co-codamol
was associated with potentially severe herb–drug in-
teractions owing to possible additive sedative effects.
34,76 One randomized controlled trial reported 1.6%
(1/61) of their participants took other medications
alongside ginger,83 and a cross-sectional survey re-
ported ginger was taken with metformin, insulin, aspi-
rin, and nifedipine and could be associated with herb–
drug interactions.76 One prospective cohort study re-
ported no increased odds of adverse pregnancy out-
comes when cranberry was used together with
antibiotics to treat urinary tract infections.72 One case
report110 mentioned additive glucose lowering effects
when insulin (Lispro) and raspberry leaf were taken
simultaneously but did not address this as a potential
herb–drug interaction.
The role of herb–drug interactions in the causa-
tion of adverse events in pregnant woman has not
been assessed. A full list of herbal medicinal products
and associated adverse events and herb–drug interac-
tions are available in Appendixes 1–4 (http://links.
lww.com/AOG/B334).
DISCUSSION
Robust studies that aim to identify and study the
causality of adverse events or herb–drug interactions
and associated adverse events arising during preg-
nancy and the postnatal period as a primary objective
are not currently available. Current data suggest that
herbal medicinal products such as almond oil, cham-
omile, licorice, and raspberry leaf used during preg-
nancy may be associated with adverse maternal and
perinatal outcomes or toxicity from contaminants.
Studies focusing on herb–drug interactions are
few, although of average to high quality, and did not
assess or report adverse events arising from identified
herb–drug interactions. Moreover, available evidence
demonstrates that widely used herbal medicinal prod-
ucts such as topical almond oil,94 chamomile,120 gin-
ger,58,61,66,67,70,74,81–84,87–89,96,99,101,105 lico-
rice,78,79,97,98 and raspberry leaf34 may be associated
with adverse perinatal outcomes. Although the major-
ity of available studies were graded as average and
many underpowered, potentially harmful adverse
events arising from use of specific herbal medicinal
products have been reported (Fig. 3).
The daily use of topical almond oil for stretch
marks during the third trimester has been reported to
increase the odds of preterm birth.94 The authors
hypothesized that continuous rubbing of the belly
might stimulate premature myometrial contractions
and that components of almond oil might act as pros-
taglandin precursors. However, only 168 women were
exposed to almond oil and the data were collected
retrospectively, therefore providing underpowered as-
sumptions and introducing recall bias. Moreover, dos-
age, surface area of application and almond
formulation used were not provided and therefore
causality cannot be objectively demonstrated.
The evidence for chamomile during pregnancy
reports increased odds of preterm delivery,99 reduced
length of newborns, and low birth weight.94 However,
both studies were underpowered and of average qual-
ity. Chamomile has also been identified as a common
source of potentially severe herb–drug interactions
when used concurrently with prescribed medi-
cines.34,76 Considering the scarce evidence available,
chamomile should be used with caution during
pregnancy.
The use of ginger during early pregnancy has
been associated with a variety of mild to severe, non–
dose-dependent adverse drug reactions, ranging from
dry mouth to worsening of nausea and dehydration89;
use during late pregnancy has been associated with
bleeding or spotting during the second and third
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trimesters,74 prematurity, and reduced head circum-
ference at birth.99 It has to be noted that formulation,
dose, and exposure period were not standardized in
these studies. Ginger has also been identified as
a source of potentially significant herb–drug interac-
tions with insulin, metformin, and nifedipine, medi-
cines commonly used during pregnancy.76
The use of raspberry leaf has been associated with
cesarean delivery by 3.5-fold34; however, this study
involved only 34 exposed women. Raspberry leaf
has also been associated with hypoglycemia when
used with insulin.110 Until there are more safety data,
it could be suggested that raspberry leaf should not be
used for labor induction because its adverse effects
may outweigh its perceived benefit.
Heavy licorice consumption (500 mg glycyrrhi-
zin/wk) throughout pregnancy was reported to
increase the odds of preterm birth (AOR 2.5, 95%
CI 1.1–5.1)97 and early preterm birth (AOR 3.07, 95%
CI 1.17–8.05).98 However, these studies were of aver-
age quality, used retrospective data and did not vali-
date exposure. Nonetheless, they had adequate
sample sizes and considered validated outcomes.
Moreover, glycyrrhizin, the active component in lic-
orice, is recognized to cause developmental
issues.78,79,121
The traditional use of mwanaphepo to induce
labor in Malawi was associated with maternal mor-
bidity (ie, emergency cesarean delivery on, assisted
vaginal delivery, PROM, among others) (AOR 1.28;
95% CI 1.09–1.50) and neonatal death or morbidity
(including neonatal death, meconium-stained amni-
otic fluid, LBW, PTB, among others) (AOR 1.22,
95% CI 1.06–1.40).100 This average quality cross-
sectional analysis used grouped retrospective data,
which may introduce bias and error,122 and did not
validate exposure to the herbal medicinal products.
Neither the dosage nor specific preparation of mwa-
naphepo were reported. Considering the latter, the
reported effect sizes in this study should be considered
weak.
The absence of adverse events were reported in
11 interventional studies assessing evening primrose
oil capsules,60 dill infusion for labor induction,80 red
sage for oligohydramnios,57 ginger for nausea and
vomiting during pregnancy,58,101 Chinese herbal
medicine for intra-uterine growth restriction,102
quince for nausea and vomiting in pregnancy,85 pine
bark103 and 1% green tea ointment63 for episiotomy
wound healing, saffron for labor induction,62 and
a polyherbal infusion to increase milk production.104
One prospective cohort study assessing tea (black
green, and herbal) consumption during pregnancy
and adverse birth outcomes also reported absence of
adverse events.71 More than half of these studies were
of poor101–104 or average quality.80,85 Moreover,
those studies deemed to be of high quality suffered
from a variety of methodologic issues, including small
sample sizes,58,62 absence of a power calculation,60
short exposure period,58 and failure to validate expo-
sure.71 Therefore, these studies should not be taken as
evidence of safety based on absence of harm, and
further robust studies are required.
This review includes all types of studies (interven-
tional, observational and case reports) that report
adverse events or herb–drug interactions arising from
herbal medicines (including polyherbals) taken during
pregnancy and the postnatal period. All interventional
and observational studies were included, regardless of
quality. However, only high-quality case reports were
included because they are considered low scientific
evidence per se. Non-English language articles were
excluded, possibly leaving out important information
from nontranslated articles. Owing to the large num-
ber of herbal medicinal products available worldwide
and the lack of standardization in reporting the names
of herbal medicinal products, it is possible that rele-
vant literature was omitted and that not all herbal
medicinal products were reported.
Collective evidence confirms that adverse events
and herb–drug interactions arising from herbal medic-
inal products used during pregnancy and the postnatal
period are under-studied and under-reported. Herb–
drug interactions are not reported or investigated in
the majority of studies. This is of concern given the
high prevalence of use of herbal and conventional
medicines during and after pregnancy.
The evidence-based use of herbal medicines
needs to be backed by robust scientific studies.
Currently, there is not enough information to recom-
mend the safe use of herbal medicinal products during
pregnancy and the postnatal period. Most herbal
medicinal products are recommended and used on
the grounds of tradition, historic or anecdotal evi-
dence. Adverse events are generally under-reported to
clinical staff, also the use of herbal medicinal products.
The U.S. Food and Drug Administration, the Euro-
pean Medicines Agency (European Union), and the
Medicines and Healthcare Products Regulatory
Agency (United Kingdom) do not subject herbal
medicinal products to the same quality standards as
medicines. Stricter pharmacovigilance measures
should be taken to avoid possible harm arising from
current herbal medicinal product use during preg-
nancy and the postnatal period. Considering the 30
years of evidence of possible harm presented, we
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conclude herbal medicinal products should not de
recommended during pregnancy until robust evi-
dence of safety is available.
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